Want to see VRCA full AI Analyst Report?
VRCA Stock Chart & Stats
$5.02
$0.31(6.08%)
At close: 4:00 PM EDT
$5.02
$0.31(6.08%)
Day’s Range― - ―
52-Week Range$3.28 - $9.82
Previous CloseN/A
Volume76.83K
Average Volume (3M)35.15K
Market Cap
$90.36M
Enterprise Value$93.55
Total Cash (Recent Filing)$20.60M
Total Debt (Recent Filing)$1.44M
Price to Earnings (P/E)―
Beta1.55
Next Earnings
Aug 06, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.56
Shares Outstanding17,178,785
10 Day Avg. Volume21,720
30 Day Avg. Volume35,153
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)3.58
Price to Sales (P/S)2.49
P/FCF Ratio-5.02
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$16.00Price Target Upside218.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-1.58
Revenue Forecast (FY)$25.53M
Bulls Say, Bears Say
Bulls Say
Commercial TractionSustained unit growth and sequential revenue gains demonstrate durable product adoption in clinic settings. Rising dispensations and >100,000 applicators since launch indicate expanding prescriber familiarity and repeat in-office usage, underpinning a predictable revenue stream as sales coverage scales.
Strong Product EconomicsVery high gross margins imply favorable unit-level profitability and efficient COGS. As commercial scale increases, these margins support sustainable contribution margins and potential rapid operating leverage, improving the odds of converting top-line growth into positive operating cash flow over the medium term.
Partnered International ExpansionA launch and substantial partner-funded R&D commitment materially lowers Verrica's cash burden and accelerates market entry. Local partner commercialization and cost-sharing reduce execution risk, enable faster enrollment and reimbursement efforts, and strengthen the global rollout and regulatory strategy.
Bears Say
Cash Burn & Runway RiskMaterial negative operating and free cash flows with runway under ~12 months create a persistent need for external capital. Fundraising risk can lead to dilution or constrained investment, making long-term programs and commercialization scale contingent on successful financing or near-term cash-positive inflection.
Operating Losses And Rising OpExElevated R&D and commercial spend relative to current revenue keeps EBIT and net margins deeply negative. Unless revenue growth sustainably outpaces these investments, persistent losses will erode flexibility and necessitate continued external funding, increasing execution and dilution risk over the medium term.
Payer/access And Gross-to-net HeadwindsCoverage, co-pay assistance costs and PBM positioning materially affect realized revenue. Transitioning prescribing beyond dermatology into pediatrics and securing PBM access are structural challenges; slow progress here can limit addressable revenue and compress net margins despite strong gross economics.
Verrica Pharmaceuticals News
VRCA FAQ
What was Verrica Pharmaceuticals’s price range in the past 12 months?
Verrica Pharmaceuticals lowest stock price was $3.28 and its highest was $9.82 in the past 12 months.
What is Verrica Pharmaceuticals’s market cap?
Verrica Pharmaceuticals’s market cap is $90.36M.
When is Verrica Pharmaceuticals’s upcoming earnings report date?
Verrica Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 5 days.
How were Verrica Pharmaceuticals’s earnings last quarter?
Verrica Pharmaceuticals released its earnings results on May 12, 2026. The company reported -$0.45 earnings per share for the quarter, missing the consensus estimate of -$0.42 by -$0.03.
Is Verrica Pharmaceuticals overvalued?
According to Wall Street analysts Verrica Pharmaceuticals’s price is currently Undervalued.
Does Verrica Pharmaceuticals pay dividends?
Verrica Pharmaceuticals does not currently pay dividends.
What is Verrica Pharmaceuticals’s EPS estimate?
Verrica Pharmaceuticals’s EPS estimate is -0.41.
How many shares outstanding does Verrica Pharmaceuticals have?
Verrica Pharmaceuticals has 17,178,785 shares outstanding.
What happened to Verrica Pharmaceuticals’s price movement after its last earnings report?
Verrica Pharmaceuticals reported an EPS of -$0.45 in its last earnings report, missing expectations of -$0.42. Following the earnings report the stock price went up 3.077%.
Which hedge fund is a major shareholder of Verrica Pharmaceuticals?
Currently, no hedge funds are holding shares in VRCA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Verrica Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$16.00 (218.73% Upside)
$16.00 (218.73% Upside)
Hedge Fund Trend
Decreased
By 325.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▼ 0.7%
Last 30 Days ▼ 0.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.28%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.04%
Trailing 12-Months
Company Description
Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
VRCA Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum for YCANTH — notably large year-over-year unit growth (51.3%), record monthly dispensing, a Japan launch and an advancing global Phase III program — and compelling Phase II clinical data for VP-315 (97% objective response, 86% tumor size reduction). These positive operational, regulatory and clinical developments are tempered by near-term financial pressures: a Q1 net loss, increased R&D and SG&A spend, modest gross-to-net variability, remaining access work particularly in pediatrics/PBMs, and a cash runway into Q1 2027 that implies a forthcoming financing need. Overall, the progress on product adoption, pipeline advancement, and international expansion outweigh the financial and access challenges reported.View all VRCA earnings summariesVRCA Stock 12 Month Forecast
Average Price Target
$16.00
▲(218.73% Upside)
Technical Analysis
Ownership Overview
47.49% Insiders
2.06% Mutual Funds
<0.01% Other Institutional Investors
48.55% Public Companies and
Individual Investors